Evidence map›Paper›PMID 41799088›Full record

ArticleACS omega2026

Hilal Fil, Ozan Yesiltepe, Simge Er Zeybekler, Ozge Kozgus, Sevinc Kurbanoglu, Emin Ilker Medine, Dilek Odaci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hilal FilDepartment of Biochemistry, Faculty of Science, Ege University, Bornova, Izmir 35100, Turkiye.
Ozan YesiltepeDepartment of Biochemistry, Faculty of Science, Ege University, Bornova, Izmir 35100, Turkiye.ORCID https://orcid.org/0000-0003-1914-1201
Simge Er ZeybeklerDepartment of Biochemistry, Faculty of Science, Ege University, Bornova, Izmir 35100, Turkiye.ORCID https://orcid.org/0000-0002-5814-0618
Ozge KozgusDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkiye.
Sevinc KurbanogluAnkara University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara 06560, Turkiye.
Emin Ilker MedineDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkiye.
Dilek OdaciDepartment of Biochemistry, Faculty of Science, Ege University, Bornova, Izmir 35100, Turkiye.ORCID https://orcid.org/0000-0002-7954-1381

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a malignancy that originates in the epithelial cells of breast tissue, presenting a considerable challenge to the physical and mental health of women worldwide. This disease remains a prominent concern in public health and medical research, necessitating ongoing attention for effective management and treatment. In this study, a novel drug delivery material was developed by using ibrutinib (IBR)-loaded electrospun polycaprolactone/poly-l-arginine (PCL-P-(Arg)) nanofibers (ENs) for breast cancer treatment. The system aims to improve site-specific delivery near breast tissue through localized and controlled drug release, offering potential advantages over conventional administration routes. The fabricated PCL-P-(Arg)/IBR ENs were characterized using Scanning Electron Microscopy-Energy Dispersive X-ray Spectroscopy (SEM-EDS), Fourier Transform Infrared Spectroscopy (FTIR), Brunauer-Emmett-Teller (BET) analysis, a swelling test, and the water vapor transmission rate (WVTR) measurements. Drug release profiles were evaluated under

Identifiers

PMID41799088
PMCPMC12961443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.